The emerging role of palliative medicine in the treatment of lung cancer patients

Cleveland Clinic Journal of Medicine

Volumn 79, Issue ELECTRONICSUPPL.1, 2012, Pages 51-55

  Davis, Mellar P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT;

CACHEXIA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; PAIN; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW;

ANALGESICS, OPIOID; ANTIPSYCHOTIC AGENTS; APPETITE STIMULANTS; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PAIN; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 84866749102     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2.11     Document Type: Article

References (27)

1. Lutz S, Norrell R, Bertucio C, et al Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 2001; 4:157-165.
2. Perrone F, Gridelli C, Cigolari S, et al. Baseline assessment of quality of life (QOL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lung cancer (NSCLC): a secondary analysis of the MILES study [ASCO abstract 1346]. Proc Am Soc Clin Oncol 2002; 21.
3. Hollen PJ, Gralla RJ, Kris MG, et al Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994; 73:2087-2098.
4. Temel JS, Greer JA, Muzikansky A, et al Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363:733-742.
5. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study [published online ahead of print March 21, 2007]. Support Care Cancer 2007; 15:1285-1291. doi: 10.1007/s00520-007-0248-5
6. Navari RM, Brenner MC Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010; 18:951-956.
7. Travers J, Dudgeon DJ, Amjadi K, et al Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol 2008; 104:57-66.
8. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010; 39:831-838.
9. Abernethy AP, McDonald CF, Frith PA, et al Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010; 376:784-793.
10. Sellner-Pogány T, Lahrmann H BIPAP-mask-ventilation in terminal amyotrophic lateral sclerosis (ALS) [in German]. Wien Med Wochenschr 2009; 159:604-607.
11. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review [published online ahead of print August 10, 2010]. J Gen Intern Med 2011; 26:70-76. doi: 10.1007/s11606-010-1472-0
12. Shimoyama N, Shimoyama M Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002; 23:73-76.
13. Papazisis KT, Kontovinis LF, Papandreou CN, et al. Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer 2010; 10:489.
14. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review [published online ahead of print July 15, 2008]. Intensive Care Med 2008; 34:2147-2156. doi: 10.1007/s00134-008-1214-5
15. Chen H-J, Yu Y-H, Tu C-Y, Chen C-H, Hsia T-C, Tsai K-D Ultrasound in peripheral pulmonary air-fluid lesions: color Doppler imaging as an aid in differentiating empyema and abscess. Chest 2009; 135:1426-1432.
16. Lichtenstein DA, Mezière GA, Lagoueyte J-F, Biderman P, Goldstein I, Gepner A A-lines and B-lines: lung ultrasound as a bedside tool for predicting pulmonary artery occlusion pressure in the critically ill. Chest 2009; 136:1014-1020.
17. Lichtenstein DA Ultrasound examination of the lungs in the intensive care unit. Pediatr Crit Care Med 2009; 10:693-698.
18. Reissig A, Heyne J-P, Kroegel C Sonography of lung and pleura in pulmonary embolism: sonomorphologic characterization and comparison with spiral CT scanning. Chest 2001; 120:1977-1983.
19. Kallet RH The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care 2007; 52:900-910.
20. Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008; 11:204-216.
21. Varkey B Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16:150-154.
22. Currow DC, Plummer J, Frith P, Abernethy AP. Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 2007; 10:1031-1036.
23. Davis MP Buprenorphine in cancer pain. Support Care Cancer 2005; 13:878-887.
24. Watson PJQ, McQuay HJ, Bullingham RES, Allen MC, Moore RA Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentrations. Br J Anaesth 1982; 54:37-43.
25. Koppert W, Ihmsen H, Körber N, et al Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118:15-22.
26. Sittl R, Likar R, Nautrup BP Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005; 27:225-237.
27. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006; 20(suppl 1):s25-s30.